Browse > Article
http://dx.doi.org/10.5051/jpis.2200340017

Azithromycin as an adjunct to subgingival professional mechanical plaque removal in the treatment of grade C periodontitis: a systematic review and meta-analysis  

Jones, Oliver P (Charles Clifford Dental Hospital)
Hoyle, Philippa J (Charles Clifford Dental Hospital)
Publication Information
Journal of Periodontal and Implant Science / v.52, no.5, 2022 , pp. 352-369 More about this Journal
Abstract
The aim of this systematic review was to evaluate clinical and microbiological outcomes with the use of azithromycin as an adjunct to non-surgical subgingival professional mechanical plaque removal (PMPR) in the treatment of grade C periodontitis. Online database searches using high-level MeSH terms in a PICO structure were conducted along with hand-searching of relevant periodontal journals. Titles and abstracts of identified studies were independently reviewed by both authors and the full texts of studies meeting the inclusion criteria were independently reviewed. In total, 122 studies were identified through searches, of which 6 were included in the qualitative analysis and 4 in the meta-analysis. Three studies included in the meta-analysis were deemed at low risk of bias and 1 at serious risk. There were conflicting results on whether azithromycin reduced the number of subgingival pathogens or detectable subgingival Aggregatibacter actinomycetemcomitans between the included studies. The meta-analysis revealed a statistically significant probing depth reduction difference in favour of azithromycin compared to the control at 3 months (weighted mean difference [WMD]=-0.39 mm; 95% confidence interval [CI], -0.66 to -0.13 mm; I2=0%) and 12 months (WMD=-1.32 mm; 95% CI, -1.71 to -0.93 mm; I2=0%). The clinical attachment level change was also statistically significant in favour of azithromycin compared to the control at 3 months (WMD=-0.61 mm; 95% CI, -1.13 to -0.10 mm; I2=71%) and 12 months (WMD=-0.88 mm; 95% CI, -1.32 to -0.44 mm; I2=0%). Based upon these results, azithromycin offers additional improvements in some clinical parameters when used in conjunction with subgingival PMPR in patients with aggressive periodontitis over control groups. These improvements appear to be maintained for up to 12 months after treatment completion. However, due to a lack of well-designed studies, the conclusions that can be drawn from the available evidence are limited.
Keywords
Aggressive periodontitis; Anti-bacterial agents; Dental scaling; Periodontitis; Systematic review;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Page MJ, Higgins JP, Sterne JA. Assessing risk of bias due to missing results in a synthesis. Cochrane handbook for systematic reviews of interventions [Internet]. London: Cochrane; 2019 [cited 2021 Aug 21]. Available from: https://training.cochrane.org/handbook.
2 GRADEpro (GDT). GRADEpro guideline development tool (software) [Internet]. Hamilton: McMaster University; 2020 [cited 2021 Jul 29]. Available from: https://www.gradepro.org/.
3 Fine DH, Patil AG, Loos BG. Classification and diagnosis of aggressive periodontitis. J Clin Periodontol 2018;45 Suppl 20:S95-111.   DOI
4 Susin C, Haas AN, Albandar JM. Epidemiology and demographics of aggressive periodontitis. Periodontol 2000 2014;65:27-45.   DOI
5 Herrera D, Sanz M, Jepsen S, Needleman I, Roldan S. A systematic review on the effect of systemic antimicrobials as an adjunct to scaling and root planing in periodontitis patients. J Clin Periodontol 2002;29 Suppl 3:136-59.   DOI
6 Eke PI, Dye BA, Wei L, Slade GD, Thornton-Evans GO, Borgnakke WS, et al. Update on prevalence of periodontitis in adults in the United States: NHANES 2009 to 2012. J Periodontol 2015;86:611-22.   DOI
7 Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Beglundh T, et al. Treatment of stage I-III periodontitis-The EFP S3 level clinical practice guideline. J Clin Periodontol 2020;47 Suppl 22:4-60.   DOI
8 Deas DE, Mealey BL. Response of chronic and aggressive periodontitis to treatment. Periodontol 2000 2010;53:154-66.   DOI
9 Rabelo CC, Feres M, Goncalves C, Figueiredo LC, Faveri M, Tu YK, et al. Systemic antibiotics in the treatment of aggressive periodontitis. A systematic review and a Bayesian Network meta-analysis. J Clin Periodontol 2015;42:647-57.   DOI
10 Keestra JA, Grosjean I, Coucke W, Quirynen M, Teughels W. Non-surgical periodontal therapy with systemic antibiotics in patients with untreated chronic periodontitis: a systematic review and metaanalysis. J Periodontal Res 2015;50:294-314.   DOI
11 Teughels W, Feres M, Oud V, Martin C, Matesanz P, Herrera D. Adjunctive effect of systemic antimicrobials in periodontitis therapy: a systematic review and meta-analysis. J Clin Periodontol 2020;47 Suppl 22:257-81.
12 American Academy of Periodontology. Proceedings of the world workshop in clinical periodontics. Chicago (IL): American Academy of Periodontology; 1989.
13 Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.   DOI
14 Papapanou PN, Sanz M, Buduneli N, Dietrich T, Feres M, Fine DH, et al. Periodontitis: consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol 2018;89 Suppl 1:S173-82.   DOI
15 Lang N, Bartold PM, Cullinan M, Jeffcoat M, Mombelli A, Murakami S, et al. Consensus report: aggressive periodontitis. Ann Periodontol 1999;4:53.   DOI
16 Albandar JM. Aggressive periodontitis: case definition and diagnostic criteria. Periodontol 2000 2014;65:13-26.   DOI
17 Caton JG, Armitage G, Berglundh T, Chapple IL, Jepsen S, Kornman KS, et al. A new classification scheme for periodontal and peri-implant diseases and conditions - Introduction and key changes from the 1999 classification. J Periodontol 2018;89 Suppl 1:S1-8.   DOI
18 Slots J, Rosling BG. Suppression of the periodontopathic microflora in localized juvenile periodontitis by systemic tetracycline. J Clin Periodontol 1983;10:465-86.   DOI
19 Saxen L, Asikainen S. Metronidazole in the treatment of localized juvenile periodontitis. J Clin Periodontol 1993;20:166-71.   DOI
20 Guerrero A, Griffiths GS, Nibali L, Suvan J, Moles DR, Laurell L, et al. Adjunctive benefits of systemic amoxicillin and metronidazole in non-surgical treatment of generalized aggressive periodontitis: a randomized placebo-controlled clinical trial. J Clin Periodontol 2005;32:1096-107.   DOI
21 British Society of Periodontology. The good practitioner's guide to periodontology [Internet]. Liverpool: British Society of Periodontology; 2016 [cited 2021 Sep 7]. Available from: https://www.bsperio.org.uk/assets/downloads/good_practitioners_guide_2016.pdf.
22 Palmer N. Antimicrobial prescribing in dentistry: good practice guidelines [Internet]. London: Faculty of General Dental Practice (UK); Faculty of Dental Surgery (UK); 2020 [cited 2021 Sep 11]. Available from: https://www.rcseng.ac.uk/-/media/files/rcs/fds/publications/fds-amp-2020.pdf.
23 Guerrero A, Echeverria JJ, Tonetti MS. Incomplete adherence to an adjunctive systemic antibiotic regimen decreases clinical outcomes in generalized aggressive periodontitis patients: a pilot retrospective study. J Clin Periodontol 2007;34:897-902.   DOI
24 Jourdan A, Sangha B, Kim E, Nawaz S, Malik V, Vij R, et al. Antibiotic hypersensitivity and adverse reactions: management and implications in clinical practice. Allergy Asthma Clin Immunol 2020;16:6.   DOI
25 Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25 Suppl A:73-82.   DOI
26 NHS England and NHS Improvement. Commissioning standard for restorative dentistry [Internet]. Leeds: NHS England and NHS Improvement; 2019 [cited 2021 Jul 1]. Available from: https://www.england.nhs.uk/wp-content/uploads/2019/07/commissioning-standard-for-restorative-dentistry-v1.pdf.
27 Haas AN, de Castro GD, Moreno T, Susin C, Albandar JM, Oppermann RV, et al. Azithromycin as an adjunctive treatment of aggressive periodontitis: 12-months randomized clinical trial. J Clin Periodontol 2008;35:696-704.   DOI
28 Emingil G, Han B, Ozdemir G, Tervahartiala T, Vural C, Atilla G, et al. Effect of azithromycin, as an adjunct to nonsurgical periodontal treatment, on microbiological parameters and gingival crevicular fluid biomarkers in generalized aggressive periodontitis. J Periodontal Res 2012;47:729-39.   DOI
29 Ercan E, Uzun BC, Ustaoglu G. Effects of azithromycin versus metronidazole-amoxicillin combination as an adjunct to nonsurgical periodontal therapy of generalized aggressive periodontitis. Niger J Clin Pract 2015;18:506-10.   DOI
30 Fujii T, Wang PL, Hosokawa Y, Shirai S, Tamura A, Hikita K, et al. Effect of systemically administered azithromycin in early onset aggressive periodontitis. Periodontal Pract Today 2004;1:321-5.
31 Haas AN, Silva-Boghossian CM, Colombo AP, Susin C, Albandar JM, Oppermann RV, et al. Adjunctive azithromycin in the treatment of aggressive periodontitis: microbiological findings of a 12-month randomized clinical trial. J Dent 2012;40:556-63.   DOI
32 Martande SS, Pradeep AR, Singh SP, Kumari M, Naik SB, Suke DK, et al. Clinical and microbiological effects of systemic azithromycin in adjunct to nonsurgical periodontal therapy in treatment of Aggregatibacter actinomycetemcomitans associated periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent 2016;7:72-80.   DOI
33 Blandizzi C, Malizia T, Lupetti A, Pesce D, Gabriele M, Giuca MR, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999;70:960-6.   DOI
34 National Institute for Health and Care Excellence (UK). Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use [Internet]. London: National Institute for Health and Care Excellence; 2015 [cited 2021 Aug 13]. Available from: https://www.nice.org.uk/guidance/ng15/resources/antimicrobialstewardship-systems-and-processes-for-effective-antimicrobial-medicine-use-pdf-1837273110469.
35 Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-63.
36 Foulds G, Johnson RB. Selection of dose regimens of azithromycin. J Antimicrob Chemother 1993;31 Suppl E:39-50.   DOI
37 Nordic Cochrane Centre; Cochrane Collaboration. Review Manager, version 5.3. London: Cochrane; 2014.
38 Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, et al. Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol 2007;78:918-23.   DOI
39 Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.   DOI
40 Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016;355:i4919.
41 Sterne JA, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898.